Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Quick facts
Phase 3 pipeline
- DCR-PHXC · Genetic/Metabolic Disease
DCR-PHXC is an RNA interference therapeutic that silences the PHXC gene to reduce production of a disease-causing protein.
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company portfolio CI brief
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company pipeline updates RSS
Frequently asked questions about Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
What is Dicerna Pharmaceuticals, Inc., a Novo Nordisk company's pipeline?
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company has 1 drugs in Phase 3, 0 in Phase 2, 4 in Phase 1. Late-stage candidates include DCR-PHXC.
Related
- Sector hub: All tracked pharma companies